FDA Rules for Health Leaders: What You Can Say About Treatments (and What You Can’t)
You know to disclose your paid partnerships. But disclosure is only half the job. When your content involves prescription drugs, medical devices, biologics, or supplements, a second federal agency has rules about what your post actually says — and right now, it is watching social media more closely than ever.
Two agencies watch health content
Both the Federal Trade Commission (FTC) and the Food & Drug Administration (FDA) watch health content.
This article will focus on the FDA rules for Health Leaders, specifically, the claims that your sponsored post makes about a product or medication.
For FTC-focused disclosure rules, read our companion guide: FTC Guidelines for Health Leaders.
Here is the part most creators miss: you can nail one lane and completely blow the other. A perfectly disclosed post can still make a claim that is not allowed.
How the FDA reaches your content
The Food and Drug Administration oversees prescription drug promotion through its Office of Prescription Drug Promotion, whose job is making sure drug promotion is truthful, balanced, and accurately communicated.1
It does not police patients sharing their lives online.
What brings your content into the FDA's eyes is the company’s involvement in it. When you partner with a company for a sponsored post, the company becomes responsible for that you say.
FDA guidance says a company is responsible for promotion on a third-party site if it has any control or influence on that site, even if that influence is limited in scope — and that if a company collaborates, or has editorial, preview, or review privilege, it is responsible for the promotion there. A company is also responsible for content generated by its employees or any agents acting on its behalf to promote its product.2
Read that list against a normal brand deal. Content the company briefs, reviews, or approves is content it has influence over. That is the mechanism: the company’s advertising rules ride along with your post.
One limit worth knowing. The same guidance says that if a company provides only financial support — an unrestricted educational grant, for example — and has no other control or influence, it is not responsible for what appears there.2 Money alone is not the trigger. Control is.
Every treatment has an indication
Every FDA-approved drug or device is approved for a specific condition, use, and population (its indication). A treatment approved for plaque psoriasis is not approved for “skin issues.” A device cleared for episodic migraine is not cleared for “headaches and stress.”
The regulations are direct about this. A prescription drug advertisement “shall not recommend or suggest any use that is not in the labeling accepted in” the approved application.3 Talking about a product beyond its indication is called off-label promotion, and in a paid campaign it is not allowed, even if the treatment really did help your fatigue, too, and even if you are just sharing your honest experience. In a paid campaign, your story has guardrails: it has to stay within the indication.
The FDA’s rules, in plain language
Stay in the approved lane. Suggesting a product works for another condition or population goes beyond the approved labeling, and the regulations do not allow it in an advertisement.3
Fair balance is the law. The rule is that risk information cannot be outweighed by benefit information — an ad is in trouble when effectiveness is presented in greater scope, depth, or detail than the risks, and is “not fairly balanced” by a summary of true information about side effects.3
In practice: risks get a real seat at the table, clearly said and clearly readable, not whispered at second 59 in tiny font.
Don’t overstate, even if it feels true. “Cleared me completely.” “Zero side effects.” “Works for everyone.” If the labeling doesn’t say it, your sponsored post can’t say it.
Supplements cannot treat diseases. A product sold as a dietary supplement but represented, explicitly or implicitly, for the treatment, prevention, or cure of a disease meets the definition of a drug and is regulated as one.4 That is why supplement labels carry “This product is not intended to diagnose, treat, cure, or prevent any disease” — only a drug can legally make such a claim.4
Your independent story is still yours. Sharing your honest experience with no brand relationship? The FDA is not policing your lived experience.
Unbranded doesn’t mean unwatched. Talking about a treatment in a paid campaign without naming it does not automatically make it safe; regulators look at the whole picture.
Say this, not that
Instead of this: "“This drug cures psoriasis!”
Say this: “After 12 weeks on this treatment, my plaques cleared. Everyone responds differently.”
Instead of this: “No side effects!”
Say this: “I personally didn’t notice side effects — everyone’s experience is different, so talk with your HCP.”
Instead of this: “It would help [other condition] too.”
Say this: I noticed a lot of improvement in my symptoms.
Instead of this: “You NEED to ask your doctor for this”
Say this: “If you’re curious, it’s worth a conversation with your doctor.”
Stay within the approved use. Full stop.
This isn’t hypothetical
In September 2025, the FDA announced a crackdown on deceptive drug advertising: thousands of warning letters, plus approximately 100 cease-and-desist letters to companies with deceptive ads.5
Social media was named specifically. The agency said that “an increasing reliance on digital and social media channels, including undisclosed paid influencer promotion, has blurred the lines among editorial content, user-generated media and pharmaceutical advertising,” and cited a 2024 study finding that 88 percent of advertisements for top-selling drugs are posted by individuals and organizations that fail to adhere to the FDA’s fair balance guidelines.5
Two things from that announcement are worth sitting with. The FDA said it is already implementing AI and other tech-enabled tools to proactively surveil and review drug ads. The monitoring is not manual and not occasional.5
And it said it is initiating rule-making to close the “adequate provision” loophole created in 1997, which companies have used to point viewers elsewhere for risk information rather than carrying it in the ad.5
Notice who receives the letters in all of this: the companies. That is the pattern worth understanding. When you partner with a brand, your words can become the company’s promotion, so the company’s regulatory problem becomes your credibility problem, even when your name is on none of the paperwork.
None of this is meant to scare you away from partnerships. It is the opposite: trained, rule-savvy health leaders have never been more valuable.
What to expect in a paid campaign
If you take a paid opportunity with a healthcare company, expect to:
- Stay on label — speak only to the approved indication, even in your personal story.
- Balance benefits with risks — safety information comes with your story, just as prominently.
- Never promise outcomes — “here’s my experience,” not “this will work for you.”
- Go through review — the company’s medical, legal, and regulatory teams will review your content before it posts. Longer timelines are the company protecting you both.
- Still follow the FTC — disclosure rules don’t go away; they stack on top.
The gut check before you post
Am I speaking as me, about my experience — or making a promise about someone else’s?
Did I give risks real airtime, not just benefits?
Am I staying inside what this product is actually approved for?
Would I be comfortable if this exact post showed up in an FDA warning letter?
The bottom line
People in our communities trust us like friends. That is exactly why regulators watch health content — and exactly why getting this right is not about fear. It is about protecting the people who trust us.
Want to go deeper? Review the FDA’s Basics of Drug Ads, enroll in the Patient Leader Certification Program, or pursue the Institute for Responsible Influence Certification to signal to brands that you know the rules.
This article is educational information, not legal advice.
Join the conversation